 | • レポートコード：MRC2211A030 • 出版社/出版日：Persistence Market Research / 2022年8月 • レポート形態：英文、PDF、168ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、頭蓋内治療薬デリバリーの世界市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症の危機分析、需要分析・予測、療法別（細胞治療、遺伝子治療、酵素補充療法（ERT））分析、疾患別（脊髄性筋萎縮症（SMA）、多発性硬化症、バッテン病、筋萎縮性側索硬化症（ALS））分析、地域別（北米、中南米、ヨーロッパ、南アジア太平洋、東アジア、中東/アフリカ）分析、仮定、調査手法などを整理しております。本書では、Novartis AG、BioMarin、CORESTEM Inc.、Alaunos Therapeutics, Inc.、Apic Bio、Stemedica Cell Technologies, Inc.、Voyager Therapeutics、Bayer AG、Abeona Therapeutics、Spark Therapeuticsなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・需要分析・予測 ・世界の頭蓋内治療薬デリバリー市場規模：療法別 - 細胞治療薬デリバリー市場規模 - 遺伝子治療薬デリバリー市場規模 - 酵素補充療法（ERT）薬デリバリー市場規模 ・世界の頭蓋内治療薬デリバリー市場規模：疾患別 - 脊髄性筋萎縮症（SMA）における市場規模 - 多発性硬化症における市場規模 - バッテン病における市場規模 - 筋萎縮性側索硬化症（ALS）における市場規模 ・世界の頭蓋内治療薬デリバリー市場規模：地域別 - 北米の頭蓋内治療薬デリバリー市場規模 - 中南米の頭蓋内治療薬デリバリー市場規模 - ヨーロッパの頭蓋内治療薬デリバリー市場規模 - 南アジア太平洋の頭蓋内治療薬デリバリー市場規模 - 東アジアの頭蓋内治療薬デリバリー市場規模 - 中東/アフリカの頭蓋内治療薬デリバリー市場規模 ・仮定 ・調査手法 |
Intracranial Therapeutic Delivery Market: Report Scope
The latest publication by Persistence Market Research on the global intracranial therapeutic delivery market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for intracranial therapeutic delivery therapies and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the intracranial therapeutic delivery market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the intracranial therapeutic delivery market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the intracranial therapeutic delivery market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the intracranial therapeutic delivery market offers information divided into three important segments – therapy, indication, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Therapy
Cell Therapy
Gene Therapy
Enzyme Replacement Therapy
Indication
Microbial Cell Culture
Mammalian Cell Culture
Plant Tissue Culture
Yeast Culture
Region
U.S.
Europe
ROW
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for intracranial therapeutic delivery over the coming years?
How will changing trends impact market growth?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the intracranial therapeutic delivery market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the intracranial therapeutic delivery market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the intracranial therapeutic delivery market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions / Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Key Promotional Strategies, By Manufacturers
4.3. Porter’s Analysis
4.4. PESTLE Analysis
4.5. Value Chain
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors – Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. GDP Growth forecast
5.2.3. Strategic Collaborations among Players
5.2.4. Rising Number of Pipeline Products for Gene-Based Therapies
5.2.5. Growing prevalence of Neurologic Diseases
5.2.6. Entries of new start-up companies in the market
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. 2021 Market Scenario
6.2. COVID-19 and Impact Analysis
6.2.1. Revenue by Therapy
6.2.2. Revenue by Indication
6.2.3. Revenue by Country
7. Global Intracranial Therapeutic Delivery Market Demand (in Value or Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032, By Therapy
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Trend Analysis By Therapy, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy, 2022–2032
8.3.1. Cell-Based Therapy
8.3.2. Gene Therapy
8.3.3. Enzyme Replacement Therapy
8.4. Market Attractiveness Analysis By Therapy
9. Global Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032, by Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032
9.3.1. Spinal Muscular Atrophy (SMA)
9.3.2. Multiple Sclerosis
9.3.3. Batten Disease
9.3.4. Amyotrophic lateral sclerosis
9.4. Market Attractiveness Analysis By Indication
10. Global Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis, By Region, 2017-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
10.3.1. U.S.
10.3.2. Europe
10.3.3. Rest of the World (ROW)
10.4. Market Attractiveness Analysis By Region
11. U.S Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
11.3.1. By Therapy
11.3.2. By Indication
11.4. Market Attractiveness Analysis
11.4.1. By Therapy
11.4.2. By Indication
11.5. Key Market Participants – Intensity Mapping
11.6. Drivers and Restraints – Impact Analysis
12. Europe Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. Italy
12.3.1.3. France
12.3.1.4. U.K.
12.3.1.5. Spain
12.3.1.6. BENELUX
12.3.1.7. Nordic Countries
12.3.1.8. Russia
12.3.1.9. Rest of Europe
12.3.2. By Therapy
12.3.3. By Indication
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapy
12.4.3. By Indication
12.5. Key Market Participants – Intensity Mapping
12.6. Drivers and Restraints – Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. Germany Intracranial Therapeutic Delivery Market
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Therapy
12.7.1.2.2. By Indication
12.7.2. France Intracranial Therapeutic Delivery Market
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Therapy
12.7.2.2.2. By Indication
12.7.3. Italy Intracranial Therapeutic Delivery Market
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast by Market Taxonomy
12.7.3.2.1. By Therapy
12.7.3.2.2. By Indication
12.7.4. Spain Intracranial Therapeutic Delivery Market
12.7.4.1. Introduction
12.7.4.2. Market Analysis and Forecast by Market Taxonomy
12.7.4.2.1. By Therapy
12.7.4.2.2. By Indication
12.7.5. U.K. Intracranial Therapeutic Delivery Market
12.7.5.1. Introduction
12.7.5.2. Market Analysis and Forecast by Market Taxonomy
12.7.5.2.1. By Therapy
12.7.5.2.2. By Indication
12.7.6. Benelux Union Intracranial Therapeutic Delivery Market
12.7.6.1. Introduction
12.7.6.2. Market Analysis and Forecast by Market Taxonomy
12.7.6.2.1. By Therapy
12.7.6.2.2. By Indication
12.7.7. Nordic Countries Intracranial Therapeutic Delivery Market
12.7.7.1. Introduction
12.7.7.2. Market Analysis and Forecast by Market Taxonomy
12.7.7.2.1. By Therapy
12.7.7.2.2. By Indication
12.7.8. Russia Intracranial Therapeutic Delivery Market
12.7.8.1. Introduction
12.7.8.2. Market Analysis and Forecast by Market Taxonomy
12.7.8.2.1. By Therapy
12.7.8.2.2. By Indication
13. Rest of the World (ROW) Intracranial Therapeutic Delivery Market Analysis 2017-2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
13.3.1. By Therapy
13.3.2. By Indication
13.4. Market Attractiveness Analysis
13.4.1. By Therapy
13.4.2. By Indication
13.5. Key Market Participants – Intensity Mapping
13.6. Drivers and Restraints – Impact Analysis
14. Market Structure Analysis
14.1. Market Analysis by Tier of Companies
14.2. Market Share Analysis of Top Players
14.3. Market Presence Analysis
14.3.1. By Regional footprint of Players
14.3.2. Product footprint by Players
14.3.3. Channel Foot Print by Players
15. Competition Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Competition Deep Dive [Tentative list]
15.3.1. Novartis AG
15.3.1.1. Overview
15.3.1.2. Product Portfolio
15.3.1.3. Key Financials
15.3.1.4. SWOT Analysis
15.3.1.5. Sales Footprint
15.3.1.6. Strategy Overview
15.3.1.7. Key Developments
15.3.2. BioMarin
15.3.2.1. Overview
15.3.2.2. Product Portfolio
15.3.2.3. Key Financials
15.3.2.4. SWOT Analysis
15.3.2.5. Sales Footprint
15.3.2.6. Strategy Overview
15.3.2.7. Key Developments
15.3.3. CORESTEM Inc.
15.3.3.1. Overview
15.3.3.2. Product Portfolio
15.3.3.3. Key Financials
15.3.3.4. SWOT Analysis
15.3.3.5. Sales Footprint
15.3.3.6. Strategy Overview
15.3.3.7. Key Developments
15.3.4. Alaunos Therapeutics, Inc.
15.3.4.1. Overview
15.3.4.2. Product Portfolio
15.3.4.3. Key Financials
15.3.4.4. SWOT Analysis
15.3.4.5. Sales Footprint
15.3.4.6. Strategy Overview
15.3.4.7. Key Developments
15.3.5. Apic Bio
15.3.5.1. Overview
15.3.5.2. Product Portfolio
15.3.5.3. Key Financials
15.3.5.4. SWOT Analysis
15.3.5.5. Sales Footprint
15.3.5.6. Strategy Overview
15.3.5.7. Key Developments
15.3.6. Stemedica Cell Technologies, Inc.
15.3.6.1. Overview
15.3.6.2. Product Portfolio
15.3.6.3. Key Financials
15.3.6.4. SWOT Analysis
15.3.6.5. Sales Footprint
15.3.6.6. Strategy Overview
15.3.6.7. Key Developments
15.3.7. Voyager Therapeutics
15.3.7.1. Overview
15.3.7.2. Product Portfolio
15.3.7.3. Key Financials
15.3.7.4. SWOT Analysis
15.3.7.5. Sales Footprint
15.3.7.6. Strategy Overview
15.3.7.7. Key Developments
15.3.8. Bayer AG
15.3.8.1. Overview
15.3.8.2. Product Portfolio
15.3.8.3. Key Financials
15.3.8.4. SWOT Analysis
15.3.8.5. Sales Footprint
15.3.8.6. Strategy Overview
15.3.8.7. Key Developments
15.3.9. Abeona Therapeutics
15.3.9.1. Overview
15.3.9.2. Product Portfolio
15.3.9.3. Key Financials
15.3.9.4. SWOT Analysis
15.3.9.5. Sales Footprint
15.3.9.6. Strategy Overview
15.3.9.7. Key Developments
15.3.10. Spark Therapeutics
15.3.10.1. Overview
15.3.10.2. Product Portfolio
15.3.10.3. Key Financials
15.3.10.4. SWOT Analysis
15.3.10.5. Sales Footprint
15.3.10.6. Strategy Overview
15.3.10.7. Key Developments
16. Assumptions and Acronyms Used
17. Research Methodology
Table 01: U.S. & Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By TherapyTable 02: U.S. & Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Indication
Table 03: U.S. & Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Region
Table 04: U.S. Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Therapy
Table 05: U.S. Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Indication
Table 06: Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Therapy
Table 07: Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Indication
Table 08: Europe Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 09: Rest of the world (ROW) Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Therapy
Table 10: Rest of the world (ROW) Intracranial Therapeutic Delivery Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Indication